A single 60-second touch is all it takes to check your sugar levels. Enjoy that cookie and track the spike—no bloodshed required—with BlueSemi’s wellness gadget, EYVA.
With an increasing focus on metabolic health—the neglect of which has been identified as the root cause of many lifestyle diseases—Hyderabad-based startup BlueSemi has developed a Made-in-India, non-invasive wellness gadget with an AI platform called EYVA. It claims to measure blood sugar levels with up to 90% accuracy compared to diagnostic centres, following World Health Organization (WHO) standards.
Founded in 2017 with a vision of revolutionising personal health management, BlueSemi began commercial sales of EYVA in November 2023 after extensive research, testing, and beta launches. Each device is priced at ₹16,650, with an average lifespan of five years. The startup boasts selling over 10,000 units in India, each used by at least two people on average, with around 1000-2000 units sold monthly. It claims to have around 2.5 million data points for 15,000 users.
The device integrates sensor technology and artificial intelligence (AI) to measure multiple health parameters, including blood glucose, ECG, heart rate, SpO2, HbA1c, and blood pressure.
“Unlike traditional continuous glucose monitors (CGMs), EYVA is non-invasive. Users simply place a finger on the device to receive personalised health insights in real time,” explains CEO and founder Sunil Maddikatla.
“The device uses nine sensors—including visible, near-infrared, and mid-infrared—and bio-impedance and environmental sensors. The sensors are finely tuned to specific wavelengths that interact with glucose molecules in the blood. Over years of research, we identified these precise wavelengths, allowing our sensors to measure glucose levels non-invasively. The data is processed in real time, and results are delivered in under 200 milliseconds. The accompanying app utilises AI to personalise data, offering actionable advice and monitoring trends,” he elaborates.
Currently, the startup is in the process of applying for patents and has submitted research papers.
Maddikatla got the idea while working in the United Kingdom with a company that developed point-of-care diagnostic devices and later began extensive research on non-invasive glucose monitoring. He calls the AI application a personal health assistant akin to “JARVIS from Iron Man—an intuitive system that understands health and provides answers.”
EYVA has adopted a reservation-based, direct-to-consumer (D2C) model, selling its product exclusively through its website, eyva.io.
“Customers can reserve a unit for ₹499 during a three-week window. After this, they have 72 hours to complete the purchase. Once the sale is finalised, the product is dispatched promptly. This limited-time availability helps us manage our production timelines effectively while maintaining exclusivity,” explains Maddikatla.
The startup has chosen a more challenging path—producing everything possible in India across Ahmedabad, Bengaluru, and Delhi. The main PCB (printed circuit board) and all other components are manufactured domestically, except for chipsets, which are sourced internationally.
Maddikatla acknowledges that manufacturing locally is costlier and more time-intensive due to an underdeveloped ecosystem. He adds, “Importing electronics often results in customs delays, quality control issues, and intellectual property risks. We wanted EYVA to reflect the Make in India ethos truly.”
BlueSemi’s EYVA targets a broad customer base, including health-conscious individuals, families seeking preventive health measures for chronic conditions, patients participating in therapeutic programmes for diabetes, obesity, or hypertension reversal, and corporate wellness initiatives.
The startup is engaged in discussions with pharmaceutical chains and digital therapeutic providers who aim to track client progress effectively.
It is also developing partnerships with academic and medical institutions to research hyper-personalised health metrics. Future product updates will focus on refining features and adding functionalities tailored to regional and individual needs.
BlueSemi has raised $2 million in seed funding and has matched this figure in EYVA sales revenue. Most of its funding has been allocated to product development. Maddikatla hinted at developing a long-term subscription model alongside its one-time product sales. The subscription model will allow users to access advanced features and updates, creating a sustainable revenue stream.
BlueSemi’s locally manufactured EYVA combines non-invasive technology with a user-centric business model, setting a precedent for what healthcare technology in India can achieve.
